BridgeMD
DAHANCA 30: A randomized non-inferiority trial of hypoxia-profile guided hypoxic modification with nimorazole during radiotherapy/chemoradiotherapy of squamous cell carcinoma of the head and neck.
EU CTIS ID: 2024-516178-31-00
What this study is testing
To show comparable treatment response in a group of head and neck cancer patients predicted as non-responders to the hypoxic modifier nimorazol with a hypoxia gene profile, when these patients where randomized to concommitant nimorazole or not.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients with HNSCC tumors where, in accordance with DAHANCA's guidelines, hypoxic modification with nimorazole under primary radiotherapy is indicated. • In addition; a) No concurrent or earlier malignant diseases that can affect the treatment, evaluation and outcome of the actual disease b) Informed consent in accordance with regulations c) Radiotherapy planned to start within 3 weeks from inclusion d) Hypoxic status from gene profile testing must be available no later than by the initiation of radiotherapy.
You likely can't join if
- Concurrent or previous malignant disease, enrollement in a competing trial, pregnancy or breast feeding.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.